Conversant Bio

What Conversant Bio does

Conversant Bio is a privately held bioscience services company headquartered in Huntsville, Alabama, founded in 2006. The company positions itself as a trusted partner to many of the top biotech and pharma groups, suggesting it operates in the biospecimen, sample procurement, or related life-science research services space serving biopharmaceutical clients. Its scale is modest, with a headcount in the 11-50 employee range, and it has not disclosed meaningful external capital, with only a single $50,000 funding event recorded in 2015. The leadership team is led by Marshall Schreeder (CEO & Co-Founder), with Luke Doiron as Chief Commercial Officer and Jay Scherer as Chief Operating Officer, indicating a commercially and operationally oriented executive bench.

The company's product, service, technology, partnership, and customer data are not documented in the available source material beyond the firmographic profile. No revenue figures, named customer logos, product catalog, or technology stack are disclosed for Conversant Bio directly. Aggregated source content associated with the dataset primarily describes Discovery Life Sciences (dls.com), a much larger biospecimen and specialty lab services platform, but the input does not establish a confirmed corporate relationship between Conversant Bio and Discovery Life Sciences. As a result, any inference about Conversant Bio's offerings beyond its positioning as a bioscience partner to biopharma clients would not be grounded in the provided evidence.

From a business-model perspective, the company appears to operate a B2B services motion targeting enterprise biotech and pharma customers, likely through direct sales given its small employee base and lack of disclosed e-commerce or self-serve channels. Pricing is not publicly disclosed, and the company's go-to-market details, revenue mechanics, and competitive positioning cannot be reliably characterized from the available data. Investors should treat the public information on Conversant Bio as sparse and any deeper commercial diligence as requiring primary research.

Name

Conversant Bio

Legal name

Discovery Life Sciences

Website

https://conversantbio.com

Company type

Private

Founded year

2006

Headcount range

11–50 employees

Short description

Conversant Bio is a privately held, Huntsville-based bioscience services company founded in 2006 that serves as a trusted partner to top biotech and pharma groups, with 11-50 employees and minimal disclosed capital activity.

Ownership category

akta.pro rank

Product category

Biospecimen Research Services

NAICS

Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Proteomics & Biomarker Analytical Testing (HLAGADAG)

akta.pro secondary industries

Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Biospecimen supply
• Biotech research samples
• Pharma research services
• Clinical trial samples
• Biological sample procurement

Headquarters

HQ city

Huntsville

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. Biospecimen Sales: Sale of assay-ready biospecimens including viable cells, tissues, FFPE samples, blood products, and NGS-characterized specimens. Products are offered at various characterization levels (RUO, GMP) and sourced through a global clinical network and prospective collection.
2. Specialty Lab Services: Integrated multi-omic lab services including genomics (whole genome sequencing, RNA-Seq, exome/targeted sequencing, single cell sequencing), proteomics (Olink, mass spectrometry), molecular pathology (IHC, multiplex IF, spatial biology), cell biology (flow cytometry, live-cell imaging, cytokine analysis), and Gentest® ADME services. Services support preclinical, translational, and clinical trial phases.
3. In Vitro Preclinical Products: Sale of in vitro products including hepatocytes (Gentest® Hepatocytes), tissue fractions (Supersomes®, Microsomes, TransportoCells™), and cell-based systems used in drug metabolism and toxicity testing.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Conversant Bio is a private biospecimen supplier and research services provider headquartered in Huntsville, Alabama, founded in 2006. The company serves as a trusted partner to top biotech and pharma groups, providing human biological samples (biospecimens) and related specialty research support to enable drug discovery, preclinical development, and clinical research programs for pharmaceutical, biotechnology, cell and gene therapy, and diagnostic customers.

Product overview

Discovery Life Sciences offers a unified platform combining biospecimens with integrated specialty laboratory services. The core offering includes assay-ready biospecimens (viable cells, tissues, blood products, biofluids) powered by a global clinical network and prospective collection expertise. The product portfolio spans AllCells® CGT Starting Material for cell and gene therapy, SpecimenSeq™ NGS-characterized biospecimens with genomic characterization, and Gentest® products including hepatocytes and tissue fractions for in vitro ADME research. These biospecimens are paired with multi-omic specialty lab services including genomics (whole genome, RNA-seq, exome, single cell), proteomics (Olink, mass spectrometry), molecular pathology (IHC, multiplex IF, digital pathology), and cell biology services (flow cytometry, live-cell imaging, spatial biology). The company serves biopharma, cell and gene therapy, clinical diagnostics, and government/nonprofit/academic research markets.

Differentiator

Problem solved

Functional benefit

Products and services

• Biospecimen Supply
• Specialty Lab Research Services

Quantifiable outcome

• Over 1,200 IND-enabling studies supported by Gentest® ADME solutions
• +2 more outcomes

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Three partnerships are on record, tiered core.

• PathAIcoreTechnology or IntegrationPathAI partnered with Discovery Life Sciences to deploy the first AI-powered biospecimen solutions. This partnership integrates PathAI's AI-powered digital pathology capabilities with Discovery's biospecimen inventory and characterization services, enabling enhanced biospecimen analysis and selection for research and clinical applications.
• DNAnexuscoreTechnology or IntegrationDNAnexus partnered with Discovery Life Sciences to streamline precision health data analysis. This collaboration integrates Discovery's multi-omic laboratory services and biospecimen data with DNAnexus's bioinformatics and data analysis platform, enabling end-to-end precision health data workflows.
• Discovery Partners ProgramcoreChannel Partner/ Reseller/ DistributorA formal partner ecosystem program inviting other companies and organizations in the biospecimens and lab services ecosystem to partner with Discovery Life Sciences for referral, co-selling, and collaborative engagement.

Scale indicators6 records

Recent moves2 records

Direct peers

• iSpecimen: iSpecimen operates a marketplace for human biospecimens connecting suppliers with researchers, overlapping directly with Conversant Bio's biospecimen procurement and distribution business for biopharma R&D use cases.
• Cureline: Cureline is a biospecimen CRO focused on prospective collection and processing of human tissues for translational research, comparable to Conversant Bio's prospective collection capabilities and global clinical network.
• BioIVT: BioIVT is one of the largest independent providers of human biospecimens and research services, directly competing with Conversant Bio/Discovery Life Sciences in supplying characterized tissues, blood products, and matched sets to biopharma and academic clients.

Broad incumbents

• IQVIA: IQVIA's broader clinical and lab services portfolio (including Q² Solutions) overlaps with Conversant Bio's clinical trial testing, biomarker services, and central lab capabilities for biopharma customers.
• Brooks Life Sciences (Azenta): Azenta (formerly Brooks Life Sciences) provides sample management, biobanking, and genomic services, overlapping with Conversant Bio's biospecimen storage, characterization, and genomics services for research and clinical applications.
• Charles River Laboratories: Charles River Labs provides integrated drug discovery and development services, including biospecimens, ADME, and specialty lab services comparable to Conversant Bio's Gentest® ADME and translational services offerings.
• Labcorp (Covance): Labcorp/Covance operates a global clinical and preclinical lab services platform that competes across Conversant Bio's specialty lab services, central labs, and biospecimen-enabled clinical trial testing.

Emerging players

• Precision Medicine Group: Precision Medicine Group supports biomarker-driven clinical trials with specialty lab and biospecimen services, comparable to Conversant Bio's companion diagnostic development and clinical trial testing offerings.
• Sanguine Biosciences: Sanguine sources biospecimens and patient-derived data directly from consented donors for biopharma research, competing in similar use cases (matched samples, prospective collection) but with a more decentralized, donor-direct model.
• Folio Biosciences: Folio Bio provides characterized human biospecimens and cell-based products for oncology and immunology research, comparable in scale and use case to a portion of Conversant Bio's viable cells and matched sets portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/conversantbio
• Facebookfacebook.com/conversantbiologics
• LinkedInlinkedin.com/company/conversant-biologics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Conversant Bio